Two Surgical Approaches for Rectal Cancer: What a 2026 RCT Found About Quality of Life

For people facing surgery for rectal cancer, one of the central questions alongside cancer control is what life will look like afterwards. Bowel function, continence, and overall quality of life all shift after rectal surgery, and the choice of surgical approach is one of the factors that may influence those outcomes. A 2026 multicentre randomised controlled trial -- the Ta-LaTME study -- set out to compare two of the most used approaches directly, following patients for five or more years.

What Is Total Mesorectal Excision?

Total mesorectal excision (TME) is the standard surgical technique for mid and low rectal cancer. It involves removing the rectum together with the surrounding envelope of tissue called the mesorectum, which contains the lymph nodes where cancer cells most commonly spread first. The technique became the benchmark for rectal cancer surgery because it substantially reduces the risk of cancer remaining in the pelvis after the operation.

TME can be performed using different access methods. The traditional approach is laparoscopic (keyhole surgery), working from above through the abdomen. A newer technique -- transanal total mesorectal excision, or TaTME -- adds an approach from below, through the anus, to dissect the lower part of the rectum. TaTME was developed partly to address the difficulty of accessing very low rectal tumours in patients with a narrow pelvis or a high body mass index.

The Connection to Stomas

A key element of many TME operations is the creation of a temporary loop ileostomy. This is a short-term stoma -- an opening in the abdomen where the small bowel is brought to the skin surface to divert faecal output. The purpose of a temporary ileostomy is to allow the surgical join between the remaining bowel and the anal canal (the anastomosis) to heal without being exposed to stool. The NHS notes that patients undergoing bowel cancer surgery may need a colostomy or ileostomy, which may be temporary or permanent, depending on surgical findings and individual recovery.

Most patients with a temporary loop ileostomy have it reversed several months after their original surgery, once the anastomosis has healed and has been assessed with an imaging check. Understanding bowel function after the reversal -- what to expect in terms of continence, urgency, and frequency -- is one of the questions that often matters most to patients in this group.

What the 2026 Trial Found

A multicentre randomised controlled trial published in BJS Open in July 2026 (pubmed:42551037) randomised 116 patients with mid or low rectal adenocarcinoma to either laparoscopic TME (57 patients) or transanal TME (59 patients), with a minimum five-year follow-up. 105 patients were included in the main analysis. Quality of life was measured using the EORTC QLQ-C30 and QLQ-CR29 questionnaires. Bowel dysfunction was assessed using the Low Anterior Resection Syndrome (LARS) score, a validated tool that measures continence, urgency, and bowel frequency after rectal surgery. Long-term cancer outcomes were also recorded.

Quality of Life

Both groups reported high global health status scores after surgery. The median EORTC QLQ-C30 global health score was 83.3 in both groups, and scores across functional scales (physical, role, emotional, cognitive, and social functioning) were comparable between the two techniques. The overall quality-of-life picture was positive for both approaches.

Bowel Function

This is where the results diverged most noticeably. Patients in the transanal group reported higher rates of stool frequency, flatulence, and faecal incontinence compared to the laparoscopic group. The proportion of patients experiencing major LARS (a LARS score of 30 or above, reflecting clinically significant bowel dysfunction) was 44% in the transanal group versus 30% in the laparoscopic group. Median LARS scores were 27 (transanal) and 24 (laparoscopic), both in the minor LARS range. The difference in symptom rates is a meaningful finding for patients deciding which approach to discuss with their surgeon, even though median scores fell in a similar range.

Long-Term Cancer Control

There were no statistically significant differences between the two approaches in oncological outcomes. Local recurrence (cancer returning in the same area) occurred in 3.7% of transanal patients versus 6.4% of laparoscopic patients. Distant recurrence occurred in 18.5% versus 14.9%. Neither difference was statistically significant. Disease-free survival and overall survival were also equivalent between the groups at five or more years of follow-up.

What This Means for Patients

The trial's authors concluded that both TaTME and laparoscopic TME achieved excellent overall quality-of-life outcomes with no substantial between-group difference in that measure, and that long-term cancer control was oncologically equivalent. The higher rate of major bowel dysfunction symptoms in the transanal group is, however, a clinically relevant finding. For patients who place high priority on bowel continence and symptom control after surgery, this is information worth discussing with a surgical team.

It is important to note that both the tumour's location in the rectum and individual patient anatomy (pelvic shape, body composition) influence which approach a surgeon may recommend or be best placed to perform. The trial provides evidence at the group level: outcomes for individuals vary, and not every patient is a candidate for both techniques.

A conversation with your surgeon about expected bowel function outcomes -- alongside cancer control rates -- is a reasonable part of the surgical planning discussion.